Today the company reported a first-quarter loss as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
Following 10 years of leadership in the market access and reimbursement marketing space, Navisync, an NPG Health company, is proud to unveil new branding—including a new logo and new agency cornerstones.
The company announced today that its drug, Rinvoq, for treating a type of inflammatory skin condition, was found to be more effective than Regeneron Pharmaceuticals and Sanofi’s Dupixent in a late-stage head-to-head study.
By not only tackling high costs but also elevating patient experiences by enhancing efficiency and outcomes, this technology stands ready to revolutionize many aspects of the industry, says GlobalData.
Yesterday that FDA approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.
